Cancer Immunotherapy Market Size, Share, By Product Type (Monoclonal Antibodies, Immunomodulators, Checkpoint Inhibitors, Adoptive Cell Therapy, and Others), By Cancer Type (Lung Cancer, Colorectal Cancer, Melanoma, Breast Cancer, Head & Neck Cancer, Prostate Cancer, and Others), By End User (Hospitals, Cancer Research Centers, and Others), and By Region - Trends, Analysis and Forecast till 2034

Cancer Immunotherapy Market Size was valued at USD 158.5 Billion in 2024 and is expected to reach USD 530.2 Billion by 2034, growing at a CAGR of 14.2%

Cancer immunotherapy is a novel and promising approach to cancer treatment in which one's immune system is regulated to fight malignant cells. This novel method of cancer treatment stimulates or enhances the immune system's innate defense mechanisms, thereby increasing its ability to recognize and fight tumor cells. Whereas traditional cancer treatments, such as chemotherapy or radiation, target cancer cells while affecting healthy tissues, immunotherapy focuses on improving the body's intrinsic ability to fight the illness. Cancer immunotherapy research is progressing, with efforts currently focused on combination medicines, tailored approaches based on specific patients' genetic profiles, and ways to expand immunotherapy's advantages to new types of cancer. Cancer immunotherapy is expected to define one of the most significant paradigm shifts in oncology, providing new hope to patients and paving the way for future cancer treatments that are more focused, effective, and less hazardous.